Correlation Engine 2.0
Clear Search sequence regions


  • amyloid (2)
  • brain (1)
  • cognitive (3)
  • dementia (1)
  • diagnosis (1)
  • female (1)
  • humans (1)
  • impairment (1)
  • mode (8)
  • positron (1)
  • Sizes of these terms reflect their relevance to your search.

    Down syndrome (DS) is associated with increased risk for Alzheimer's disease (AD). In neurotypical individuals, clinical AD is preceded by reduced resting state functional connectivity in the default mode network (DMN), but it is unknown whether changes in DMN connectivity predict clinical onset of AD in DS. Does lower DMN functional connectivity predict clinical onset of AD and cognitive decline in people with DS? Resting state functional MRI (rsfMRI), longitudinal neuropsychological, and clinical assessment data were collected on 15 nondemented people with DS (mean age = 51.66 years, SD = 5.34 years, range = 42-59 years) over four years, during which 4 transitioned to dementia. Amyloid-β (Aβ) PET data were acquired on 13 of the 15 participants. Resting state fMRI, neuropsychological, and clinical assessment data were also acquired on an independent, slightly younger unimpaired sample of 14 nondemented people with DS (mean age = 44.63 years, SD = 7.99 years, range = 38-61 years). Lower functional connectivity between long-range but not short-range DMN regions predicts AD diagnosis and cognitive decline in people with DS. accumulation in the inferior parietal cortex is associated with lower regional DMN functional connectivity. Reduction of long-range DMN connectivity is a potential biomarker for AD in people with DS that precedes and predicts clinical conversion.

    Citation

    Natalie D DiProspero, David B Keator, Michael Phelan, Theo G M van Erp, Eric Doran, David K Powell, Kathryn L Van Pelt, Frederick A Schmitt, Elizabeth Head, Ira T Lott, Michael A Yassa. Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome. Journal of Alzheimer's disease : JAD. 2022;85(1):153-165

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34776436

    View Full Text